首页|盐酸氨溴索联合特布他林、皮下特异性免疫治疗COPD稳定期伴变应性鼻炎的效果及对基质金属蛋白酶水平的影响

盐酸氨溴索联合特布他林、皮下特异性免疫治疗COPD稳定期伴变应性鼻炎的效果及对基质金属蛋白酶水平的影响

扫码查看
目的 探讨盐酸氨溴索联合特布他林、皮下特异性免疫治疗慢性阻塞性肺疾病(COPD)稳定期伴变应性鼻炎的效果。方法 选取2019年6月至2022年6月我院收治的50例COPD稳定期伴变应性鼻炎患者为研究对象,按治疗方式差异将其分为对照组(25例,特布他林+皮下特异性免疫治疗)和观察组(25例,在对照组基础上联合盐酸氨溴索治疗)。比较两组的治疗效果。结果 观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0。05)。治疗后,观察组的基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)水平低于对照组,差异具有统计学意义(P<0。05)。治疗后,观察组的Toll样受体4(TLR4)、程序性死亡受体-1(PD-1)水平低于对照组,差异具有统计学意义(P<0。05)。治疗后,观察组的辅助性T细胞17(Th17)、免疫球蛋白E(IgE)水平低于对照组,差异具有统计学意义(P<0。05)。结论 盐酸氨溴索联合特布他林、皮下特异性免疫治疗可有效提高COPD稳定期伴变应性鼻炎患者的临床效果,调节基质金属蛋白酶水平,改善炎症、免疫等相关因子水平,值得推广。
Effect of ambroxol hydrochloride combined with terbutaline and subcutaneous specific immunotherapy on stable COPD with allergic rhinitis and its influence on matrix metalloproteinase level
Objective To investigate the effect of ambroxol hydrochloride combined with terbutaline and subcutaneous specific immunotherapy on stable chronic obstructive pulmonary disease(COPD)with allergic rhinitis.Methods A total of 50 patients with stable COPD and allergic rhinitis admitted in our hospital from June 2019 to June 2022 were selected as the research objects.According to the difference of treatment methods,the patients were divided into control group(25 cases,terbutaline+subcutaneous specific immunotherapy)and observation group(25 cases,combined with ambroxol hydrochloride treatment on the basis of the control group).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of matrix metalloproteinase-9(MMP-9)and tissue inhibitor of metalloproteinase-1(TIMP-1)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of Toll-like receptor 4(TLR4)and programmed death-1(PD-1)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the T helper cell 17(Th 17)and immunoglobin E(IgE)level in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Ambroxol hydrochloride combined with terbutaline and subcutaneous specific immunotherapy can effectively improve the clinical effect of patients with stable COPD and allergic rhinitis,regulate the level of matrix metalloproteinase,and improve the levels of inflammation,immunity and other related factors,which is worthy of promotion.

ambroxol hydrochlorideterbutalinesubcutaneous specific immunotherapychronic obstructive pulmonary diseaseallergic rhinitis

刘晓东、柳双双、牛永亮

展开 >

神木市医院,陕西榆林,719300

盐酸氨溴索 特布他林 皮下特异性免疫治疗 慢性阻塞性肺疾病 变应性鼻炎

2022年陕西省卫生健康科研项目

2022C006

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(20)